bluebird bio (BLUE) Rating Reiterated by Oppenheimer

bluebird bio (NASDAQ:BLUE)‘s stock had its “hold” rating reaffirmed by research analysts at Oppenheimer in a note issued to investors on Friday.

Several other research firms have also weighed in on BLUE. ValuEngine upgraded shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Goldman Sachs Group lowered shares of bluebird bio from a “conviction-buy” rating to a “buy” rating in a research report on Friday, September 21st. Wedbush reduced their price target on shares of bluebird bio from $204.00 to $166.00 and set an “outperform” rating for the company in a research report on Monday, November 5th. Guggenheim began coverage on shares of bluebird bio in a research report on Monday, September 17th. They set a “neutral” rating for the company. Finally, Morgan Stanley dropped their price objective on shares of bluebird bio from $186.00 to $185.00 and set an “equal weight” rating on the stock in a report on Monday, November 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $188.83.

Shares of NASDAQ BLUE traded down $1.61 during trading on Friday, hitting $115.28. The stock had a trading volume of 383,458 shares, compared to its average volume of 574,441. bluebird bio has a 12 month low of $87.49 and a 12 month high of $236.17. The firm has a market cap of $6.03 billion, a price-to-earnings ratio of -14.95 and a beta of 2.41.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.90) by $0.17. bluebird bio had a negative net margin of 1,326.02% and a negative return on equity of 31.50%. The firm had revenue of $11.50 million during the quarter, compared to analyst estimates of $6.90 million. During the same quarter in the prior year, the business posted ($1.73) EPS. The business’s revenue was up 49.2% compared to the same quarter last year. Equities analysts forecast that bluebird bio will post -10.76 EPS for the current fiscal year.

In related news, insider David Davidson sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 2nd. The shares were sold at an average price of $133.64, for a total value of $668,200.00. Following the transaction, the insider now directly owns 29,905 shares in the company, valued at $3,996,504.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Susanna Gatti High sold 1,890 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $113.83, for a total transaction of $215,138.70. Following the completion of the transaction, the chief operating officer now owns 15,610 shares in the company, valued at $1,776,886.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,777 shares of company stock worth $3,290,502. Insiders own 3.00% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Casdin Capital LLC increased its position in shares of bluebird bio by 37.9% in the second quarter. Casdin Capital LLC now owns 200,000 shares of the biotechnology company’s stock worth $31,390,000 after purchasing an additional 55,000 shares during the last quarter. Xact Kapitalforvaltning AB increased its position in shares of bluebird bio by 17.7% in the third quarter. Xact Kapitalforvaltning AB now owns 8,630 shares of the biotechnology company’s stock worth $1,260,000 after purchasing an additional 1,300 shares during the last quarter. Bank of America Corp DE increased its position in shares of bluebird bio by 26.6% in the second quarter. Bank of America Corp DE now owns 155,890 shares of the biotechnology company’s stock worth $24,467,000 after purchasing an additional 32,724 shares during the last quarter. Vident Investment Advisory LLC increased its position in shares of bluebird bio by 37.0% in the second quarter. Vident Investment Advisory LLC now owns 13,501 shares of the biotechnology company’s stock worth $2,119,000 after purchasing an additional 3,643 shares during the last quarter. Finally, Credit Suisse AG increased its position in shares of bluebird bio by 26.6% in the third quarter. Credit Suisse AG now owns 259,738 shares of the biotechnology company’s stock worth $37,921,000 after purchasing an additional 54,498 shares during the last quarter.

About bluebird bio

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Story: Earnings Reports

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply